Kromek Group PLC (AIM:KMK) today holds its Capital Markets Day, during which it will brief analysts and institutional investors on its strategy for growth.
Kromek, in a quick statement, said no new information is being disclosed, but repeated comments from May’s trading update in which it said it expected to report financial year 2025 revenue ahead of market expectations (not less than £26 million).
This would represent year-on-year growth of at least 34%, it noted.
The performance is being driven by Kromek’s partnership with Siemens’ Healthineers business.
Looking ahead, Kromek, which develops and sells radiation and bio-detection technology, also repeated to investors that it is targeting medium-term revenue of over £60 million and a 30% EBITDA margin.
Preceding the CMD later today,y it also highlighted that in FY 2024, its Advanced Imaging unit generated £9 million of revenue and the CBRN Detection business brought in £10.4 million – taking total group revenue to £19.4 million for last year.